Thomas Jefferson University

Laura Doyle

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address1025 Walnut Street
Philadelphia PA 19107
Phone2155037207
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bundalevski I, Harrison AS, Dzeda MF, Doyle LA, Chen H. Use of 3D Printing Technology to Improve Lead Shield Fabrication for Electron Therapy of the Face. Pract Radiat Oncol. 2025 Jan 15. PMID: 39818683.
      Citations:    
    2. Maduro Bustos LA, Sarkar A, Doyle LA, Andreou K, Noonan J, Nurbagandova D, Shah SA, Irabor OC, Mourtada F. Feasibility evaluation of novel AI-based deep-learning contouring algorithm for radiotherapy. J Appl Clin Med Phys. 2023 Jul 18; e14090. PMID: 37464581.
      Citations:    
    3. Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 02; 40(1):115-123. PMID: 34515877.
      Citations:    
    4. Taylor JM, Song A, Nowak K, Dan T, Simone B, Harrison A, Doyle L, Lockamy V, Anne P, Simone N. Dosimetric Comparisons of Simulation Techniques for Left-Sided Breast Cancer in the COVID-19 Era: Techniques to Reduce Viral Transmission and Respect the Therapeutic Ratio. Cureus. 2021 Feb 15; 13(2):e13354. PMID: 33747655.
      Citations:    
    5. Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clin Transl Sci. 2020 11; 13(6):1178-1188. PMID: 32738099.
      Citations:    
    6. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 Jul; 21(7):957-968. PMID: 32553118.
      Citations:    
    7. Den RB, Greenspan J, Doyle LA, Harrison AS, Peng C, Williams NL, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer. Brachytherapy. 2020 Mar 23. PMID: 32217038.
      Citations:    
    8. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020 04 09; 382(15):1430-1442. PMID: 32187457.
      Citations:    
    9. Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546. PMID: 32083163.
      Citations:    
    10. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78. PMID: 31277699.
      Citations:    
    11. Bar-Ad V, Hubley E, Luginbuhl A, Cognetti D, Curry J, Harrison AS, Johnson JM, Keller J, Peng C, To D, Doyle L. Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma. J Contemp Brachytherapy. 2019 Jun; 11(3):227-234. PMID: 31435429.
      Citations:    
    12. Walsh A, Hubley E, Doyle L, Cognetti D, Curry J, Bar-Ad V, Luginbuhl A. Carotid dosimetry after re-irradiation with 131Cs permanent implant brachytherapy in recurrent, resected head and neck cancer. J Contemp Brachytherapy. 2019 Jun; 11(3):221-226. PMID: 31447900.
      Citations:    
    13. Hubley E, Trager M, Bar-Ad V, Luginbuhl A, Doyle L. A nomogram to determine required seed air kerma strength in planar 131Cesium permanent seed implant brachytherapy. J Contemp Brachytherapy. 2019 Feb; 11(1):91-98. PMID: 30911315.
      Citations:    
    14. Rodin J, Bar-Ad V, Cognetti D, Curry J, Johnson J, Zender C, Doyle L, Kutler D, Leiby B, Keane W, Luginbuhl A. A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery. J Contemp Brachytherapy. 2018 Oct; 10(5):454-462. PMID: 30479623.
      Citations:    
    15. Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 09; 72:92-95. PMID: 30118897.
      Citations:    
    16. Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res. 2017 10; 61:108-116. PMID: 28957699.
      Citations:    
    17. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):516-522. PMID: 27978579.
      Citations:    
    18. LaCerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clin Cancer Res. 2017 Jul 15; 23(14):3592-3600. PMID: 28174232.
      Citations:    
    19. Doyle LA, Yondorf M, Peng C, Harrison AS, Den RB. Process Mapping and Time Study to Improve Efficiency of New Procedure Implementation for High-Dose Rate Prostate Brachytherapy. J Healthc Qual. 2016 Nov 01. PMID: 27811578.
      Citations:    
    20. Dan TD, Doyle L, Raval AJ, Pridjian A, Gomella LG, Den RB. Dosing, administration, and safety of radium-223: How I do it. Can J Urol. 2016 Jun; 23(3):8301-5. PMID: 27347625.
      Citations:    
    21. Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Bar-Ad V, Dicker A, Doyle L, Li J, Sato T. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol. 2016 Apr; 39(2):189-95. PMID: 24441583.
      Citations:    
    22. Nowak K, Bar-Ad V, Ferguson L, McAna J, Harrison AS, Yu Y, Doyle L. Using the ACR Accreditation Process As a Quality Improvement Tool. J Am Coll Radiol. 2016 Jul; 13(7):881-3. PMID: 26908397.
      Citations:    
    23. Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep; 100(9):1172-9. PMID: 26022709.
      Citations:    
    24. Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, Doroshow JH, Kummar S. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest New Drugs. 2015 Jun; 33(3):720-8. PMID: 25637165.
      Citations:    
    25. Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21(7):1558-65. PMID: 25467181.
      Citations:    
    26. Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H, Blaney SM. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4. PMID: 25446280.
      Citations:    
    27. Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62. PMID: 25248382.
      Citations:    
    28. Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep-Oct; 13(5):456-64. PMID: 24953945.
      Citations:    
    29. Den RB, Doyle LA, Knudsen KE. Practical guide to the use of radium 223 dichloride. Can J Urol. 2014 Apr; 21(2 Supp 1):70-6. PMID: 24775727.
      Citations:    
    30. Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2014 Jul; 61(7):1246-51. PMID: 24664955.
      Citations:    
    31. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795.
      Citations:    
    32. Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? Expert Rev Anticancer Ther. 2014 Jan; 14(1):39-50. PMID: 24124755.
      Citations:    
    33. Zaorsky NG, Den RB, Doyle LA, Dicker AP, Hurwitz MD. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Rev Med Devices. 2013 Nov; 10(6):751-63. PMID: 24195459.
      Citations:    
    34. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622.
      Citations:    
    35. Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev. 2014 Apr; 40(3):414-25. PMID: 24231548.
      Citations:    
    36. Piana PM, Bar V, Doyle L, Anne R, Sato T, Eschelman DJ, McCann JW, Gonsalves CF, Brown DB. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford). 2014 Apr; 16(4):336-41. PMID: 23782387.
      Citations:    
    37. Chapman KL, Ohri N, Showalter TN, Doyle LA. Optimizing parametrial aperture design utilizing HDR brachytherapy isodose distribution. J Contemp Brachytherapy. 2013 Mar; 5(1):50-4. PMID: 23634156.
      Citations:    
    38. Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN. Radiotherapy Protocol Deviations and Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials. J Natl Cancer Inst. 2013 Mar 20; 105(6):387-93. PMID: 23468460.
      Citations:    
    39. Harrison AS, Yu Y, Dicker AP, Doyle LA. Using qualitative measures to improve quality in radiation oncology. Am J Med Qual. 2013 Jul-Aug; 28(4):345-51. PMID: 23042915.
      Citations:    
    40. Doyle L, Hesney AJ, Chapman KL, Liu H, Weiner PR, Dicker AP, Yu Y, Showalter TN. Re-implantation of suboptimal prostate seed implantation: technique with intraoperative treatment planning. J Contemp Brachytherapy. 2012 Sep; 4(3):176-81. PMID: 23346147.
      Citations:    
    41. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov; 97(11):1736-42. PMID: 22733022.
      Citations:    
    42. Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol. 2012 Oct; 127(1):55-62. PMID: 22664059.
      Citations:    
    43. Lawrence YR, Whiton MA, Symon Z, Wuthrick EJ, Doyle L, Harrison AS, Dicker AP. Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys. 2012 Nov 1; 84(3):590-5. PMID: 22445006.
      Citations:    
    44. Shen X, Dicker AP, Doyle L, Showalter TN, Harrison AS, Desharnais SI. Pilot study of meaningful use of electronic health records in radiation oncology. J Oncol Pract. 2012 Jul; 8(4):219-23. PMID: 23185145.
      Citations:    
    45. Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol. 2011 Oct; 22(10):1373-9. PMID: 21764600.
      Citations:    
    46. Petroziello MF, McCann JW, Gonsalves CF, Eschelman DJ, Anne PR, Sato T, Doyle LA, Frangos A, Brown DB. Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. AJR Am J Roentgenol. 2011 Jul; 197(1):W169-74. PMID: 21700981.
      Citations:    
    47. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011 Feb; 196(2):468-73. PMID: 21257902.
      Citations:    
    48. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, Briel J, Doyle LA, Wright JJ, Rudek MA. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Mar 24; 117(12):3302-10. PMID: 21239698.
      Citations:    
    49. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 1; 28(31):4740-6. PMID: 20837940.
      Citations:    
    50. Doyle LA, Harrison AS, Cognetti D, Xiao Y, Yu Y, Liu H, Ahn PH, Anné PR, Showalter TN. Reirradiation of head and neck cancer with high-dose-rate brachytherapy: a customizable intraluminal solution for postoperative treatment of tracheal mucosa recurrence. Brachytherapy. 2011 Mar-Apr; 10(2):154-8. PMID: 20719575.
      Citations:    
    51. Fogh S, Doyle L, Yu A, Li J, Weiner P, Suh D, Comber E, Dicker AP, Yu Y, Xiao Y, Harrison A. A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate (125)I seed implantation. Brachytherapy. 2010 Oct-Dec; 9(4):335-40. PMID: 20226742.
      Citations:    
    52. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg. 2010 Jan; 89(1):200-6; discussion 206. PMID: 20103235.
      Citations:    
    53. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bola?os-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul; 34(7):877-82. PMID: 19962759.
      Citations:    
    54. Doyle LA, Showalter TN, Werner-Wasik M, Weksler B, Xiao Y, Yu Y, Macrone A, Liu H, Harrison A. High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy. Brachytherapy. 2010 Jan-Mar; 9(1):86-90. PMID: 19846346.
      Citations:    
    55. Edelman MJ, Suntharalingam M, Burrows W, Kwong KF, Mitra N, Gamliel Z, Riley M, Cooper LB, Kennedy NL, Buskirk S, Hausner P, Doyle LA, Krasna MJ. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg. 2008 Sep; 86(3):903-10. PMID: 18721580.
      Citations:    
    56. Bridges BB, Thomas L, Hausner PF, Doyle LA, Bedor M, Smith R, Brahmer J, Edelman MJ. Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):61-6. PMID: 18201795.
      Citations:    
    57. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008 Feb 01; 70(2):391-5. PMID: 17980508.
      Citations:    
    58. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Aug 20; 23(24):5774-8. PMID: 16110034.
      Citations:    
    59. Kwong KF, Edelman MJ, Suntharalingam M, Cooper LB, Gamliel Z, Burrows W, Hausner P, Doyle LA, Krasna MJ. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg. 2005 Jun; 129(6):1250-7. PMID: 15942564.
      Citations:    
    60. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res. 2003 Aug 15; 9(9):3320-8. PMID: 12960118.
      Citations:    
    61. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):197-9. PMID: 12581573.
      Citations:    
    Doyle's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (222)
    Explore
    _
    Co-Authors (30)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _